A growing body of research is connecting GLP-1 receptor agonists, the class of drugs behind brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, to a serious eye condition that can cause permanent vision loss. The condition has a long medical name: non-arteritic anterior ischemic optic neuropathy, or NAION. Eye specialists sometimes describe it as a stroke of the optic nerve. And once the damage is done, there is currently no treatment that can undo it.

This article is not written to frighten you or push you off your medication without talking to your physician. Millions of people are benefiting from these drugs every day. But the question health experts are now asking out loud is this: when a rare side effect starts appearing in large numbers of people, does it stay rare?

What Are GLP-1 Drugs and Why Are So Many People Taking Them?

GLP-1 stands for glucagon-like peptide-1. These drugs mimic a hormone your gut naturally releases after eating. They slow digestion, reduce hunger, and help control blood sugar. Originally developed for type 2 diabetes, they became household names when studies showed they could also produce significant weight loss.

The popularity of these drugs has been extraordinary. Roughly 15 million people in the United States are currently taking GLP-1 medications, and that number keeps climbing. Many of these users do not have diabetes at all. They are taking the drug specifically to lose weight, often without a full picture of what the long-term risks might look like.

The Eye Condition No One Was Expecting

NAION occurs when blood flow to the front portion of the optic nerve is cut off or severely reduced. The optic nerve is the cable that carries visual signals from your eye to your brain. When that nerve loses its blood supply, even briefly, it can suffer damage that leads to permanent partial or total vision loss in that eye. Health authorities, including the World Health Organization, confirm that this vision loss is usually permanent.

The condition is not brand new. It was already known to affect adults over 50, people with high blood pressure, and people with diabetes. What caught researchers off guard was a cluster of cases appearing in people who had recently started taking semaglutide-based medications.

The alarm was first raised in 2024, when physicians at Massachusetts Eye and Ear, a Harvard Medical School-affiliated hospital, published findings in the journal JAMA Ophthalmology. Their retrospective study of more than 16,000 neuro-ophthalmic patients found that people with type 2 diabetes or obesity who were taking semaglutide had a significantly higher rate of NAION compared to those taking other medications. Among diabetes patients in the study, semaglutide users showed a hazard ratio of 4.28, meaning the risk of developing NAION was more than four times higher than in comparable patients on other glucose-lowering drugs.

A separate Danish and Norwegian study that same year, drawing on data from more than 424,000 patients with type 2 diabetes, found that once-weekly semaglutide use more than doubled the five-year risk of NAION compared to patients taking other diabetes medications.

A Small Percentage Times Millions of People

Here is where the math matters. NAION is classified as “very rare,” meaning it may affect up to 1 in 10,000 people. The European Medicines Agency, which regulates drugs across 27 countries, formally added this classification in June 2025, recommending that product information for Ozempic, Wegovy, and Rybelsus be updated to include NAION as a side effect. The World Health Organization issued its own safety alert shortly after.

But consider what “very rare” actually means when tens of millions of people are taking a drug. If even 1 in 10,000 semaglutide users develops NAION, and 15 million Americans are using GLP-1 medications, that translates to roughly 1,500 potential cases in the United States alone. And that figure is based on the most conservative estimate.

The American Optometric Association’s clinical guidance report put it bluntly: “There is a low risk of serious ocular side effects. But a low risk of a big number is a big risk.”

The University at Buffalo researchers who published a related case series in JAMA Ophthalmology noted something else that raised eyebrows. NAION almost always strikes one eye at a time. But some patients on GLP-1 drugs were presenting with the condition in both eyes simultaneously, which is considered atypical and potentially more alarming.

The Research Is Still Sorting Itself Out

To be fair, the picture is not entirely clear-cut. A large February 2025 retrospective study that pooled data from 37 million diabetes patients across 14 international databases found that semaglutide users showed about 14 to 15 NAION cases per 100,000 patients annually, and when compared to other GLP-1 drugs, the risk was not significantly different. This suggests the vision risk may apply to the entire class of GLP-1 medications, not just semaglutide specifically.

A separate large cohort study published in JAMA Network Open, covering 185,000 individuals on GLP-1 drugs, found a slightly higher risk of developing diabetic retinopathy, but a similar rate of NAION compared to those on other treatments. And two studies presented at the American Academy of Ophthalmology’s 2025 annual meeting offered conflicting signals: one tied GLP-1 drugs to increased NAION risk and diabetic retinopathy risk, while another suggested the drugs might actually protect against dry age-related macular degeneration.

Scientists are careful to note that none of the current evidence proves that GLP-1 drugs cause NAION. What exists is a statistically significant association that has now been observed across multiple studies, multiple countries, and multiple drug databases. That is enough to prompt regulatory bodies to act and researchers to dig deeper.

Who May Be at Highest Risk?

Physicians are paying special attention to patients who already have underlying vascular risk factors. High blood pressure, high cholesterol, diabetes, a history of cardiovascular disease, and a structural eye condition called a small optic disc are all considered risk factors for NAION independent of GLP-1 use. When these pre-existing vulnerabilities are combined with a medication that may affect blood flow to the optic nerve, the potential for harm may be higher.

The symptoms to watch for are specific and sudden: vision loss in one eye that seems to come on without warning, often noticed upon waking. There may be a dark or blurry area in part of your field of vision, or a sense that something has been “wiped away” in one corner of sight. There is typically no pain, which is part of why people sometimes wait before seeking care. Any of these symptoms should be treated as a medical emergency.

Where Things Stand Right Now

As of June 2026, the European Medicines Agency has updated its labeling requirements for semaglutide to include NAION. The World Health Organization has issued a formal safety alert. And a multidistrict litigation involving GLP-1 vision loss lawsuits was consolidated in the Eastern District of Pennsylvania in December 2025. Legal analysts report that over 1,800 lawsuits had been filed by mid-2025, with more expected as scientific review continues.

The U.S. Food and Drug Administration has not yet added a NAION warning to American drug labels for semaglutide. Novo Nordisk, which manufactures Ozempic and Wegovy, has not yet updated its U.S. prescribing information to reflect the risk. Public health advocates and some legal experts have called for a black box warning, the FDA’s highest-level alert.

The American Academy of Ophthalmology and the North American Neuro-Ophthalmology Society have both weighed in, stating that they do not recommend that all semaglutide users stop their medication immediately if they develop NAION, since the benefits of the drug may still outweigh individual risks, depending on the patient’s overall health. But both organizations agree that sudden vision changes of any kind require immediate medical evaluation.

What This Means for You

If you are currently taking a GLP-1 medication for weight loss or diabetes management, here are the most important things to keep in mind.

1. Do not stop your medication without talking to your physician. For many people, the health benefits of these drugs are substantial, and an abrupt stop can create its own risks.
2. Tell your physician if you have existing eye problems, high blood pressure, or a history of cardiovascular disease. These factors may influence how closely you should be monitored.
3. Take sudden vision changes seriously. If you wake up one morning and something looks wrong with one eye, that is not something to wait out. Call your physician or go to an emergency room. Time may matter.
4. Ask questions. Ask your physician whether NAION has been discussed in your care plan. Ask whether your specific risk factors warrant more frequent eye exams. You have the right to that conversation

The Larger Question

GLP-1 medications have been genuinely life-changing for many people. They have helped reduce the burden of obesity, lower cardiovascular risk, and control blood sugar in ways that were difficult to achieve before. None of that is in dispute.

But when a drug reaches the scale of tens of millions of users, even rare side effects become a public health question. A risk that affects fewer than 1 in 10,000 people in a clinical trial still produces thousands of real individuals with real and permanent vision loss when multiplied across the population taking these drugs. Those individuals deserve answers, updated labels, and the chance to make informed decisions before the lights go out.

Research is ongoing. Regulatory conversations are happening. In the meantime, staying informed, staying in communication with your physician, and taking any sudden change in vision seriously are the most important steps you can take.

The post The Weight-Loss Drug Nobody Warned You About: When the Scale Goes Down, and Your Sight Goes With It appeared first on Medika Life.

The Strait also ships vaccines.

Save the Children has a consignment of urgently needed medicines stuck at a supplier’s warehouse in India. The road route is closed due to conflict. The usual fallback — air freight — has just doubled in price due to jet fuel prices. The charity’s chief executive, Janti Soeripto, put the situation to NPR earlier this month: “The transport for the drugs is more expensive than the drugs themselves.” That sentence is the story this piece is about. Not the Strait, not the oil, not even the war. The slow, awkward arithmetic by which a maritime closure thousands of miles away ends up determining whether a child in Kandahar gets a vial of antibiotics.

What the Strait actually carries

Commercial activity through Hormuz remains around 90 per cent below pre-war levels, according to analysis from the Council on Foreign Relations. Pre-conflict, around 3,000 vessels transited the strait each month; the latest House of Commons Library figures put current traffic at roughly five per cent of that. The strait is partially open, partially closed, and oscillating depending on the state of the Lebanon ceasefire and which side has most recently accused the other of violating it.

The pharmaceutical reading of those numbers takes a different shape. The Gulf Cooperation Council region serves as a transit hub linking Africa, Asia, Europe, India and the United States, and its pharmaceutical industry, valued at $23.7 billion, relies on imports through Gulf airspace and the strait for around 80 per cent of its product. Most of what matters most moves by air, not by container ship. Wouter Dewulf, professor at the University of Antwerp and a specialist in pharmaceutical logistics, told Al Jazeera last week that 35 per cent of pharmaceuticals move by air, and around 90 per cent of life-saving pharmaceuticals and vaccines do. He estimates that 22 per cent of global air cargo flows are exposed to disruptions in the Middle East.

Why a closed sea lane raises the cost of a mosquito net

The mechanism is rarely intuitive. India, which produces almost half of US generic prescriptions, depends on the strait for around 40 per cent of its crude oil imports — and that crude is the upstream feedstock for the petrochemicals used in active pharmaceutical ingredient manufacturing. With oil trading above $100 a barrel, the cost of producing the ingredient rises before a single tablet has been pressed. Indian air cargo rates have climbed 200 to 350 per cent on some routes, according to industry analysis, and war-risk insurance premiums for vessels transiting Hormuz have, by some measures, surged more than 1,000 per cent since late February.

The exposure is not abstract. The US Pharmacopeia has flagged that 48 per cent of US amoxicillin oral suspension is produced in Jordan, alongside a quarter of doxycycline hyclate capsules — common antibiotics, sourced from inside the conflict’s regional footprint.

It travels further than that. Jean Kaseya, director-general of Africa CDC, told reporters earlier this month that fuel shortages are pushing up the cost of producing mosquito nets, which are made from polyester, which is made from petrochemicals, which depend on a sea lane currently being charged at over a million dollars a transit when it is open at all. Malaria control is now, by an unobvious chain of reasoning, also a Hormuz story.

And the medicines that can’t wait

Of all the downstream consequences, the cold chain is the most exposed. Vaccines, insulin, biologics, and cancer therapies must be maintained within a narrow temperature range, typically between 2 and 8 degrees Celsius. Most of those products move by air, not sea, and most of the world’s high-volume air corridors run through Gulf hubs that have been variously closed, struck or rerouted around. Prashant Yadav, senior fellow for global health at the Council on Foreign Relations and one of the leading specialists in the field, has pointed to the timing problem with characteristic clarity: cargo carriers need roughly a week and a half to recover for every week of suspended shipments.

The arithmetic compounds.

It is partly a structural constraint. Yadav has also noted that European airlines and the two African carriers that have stepped in are unlikely to add new cargo capacity, as the disruption might continue for a few more months. Capacity is not bought overnight, and the current ceiling is, more or less, the medium-term one.

The countries most exposed are those already short of a buffer. The European Union has a stockpiling mechanism. The UK has flagged the risk of medicine shortages within weeks, but holds some reserve. The United States ordered a six-month stockpile of essential medicines last year. Sub-Saharan Africa, by contrast, imports around 70 per cent of its pharmaceuticals and runs far closer to the wire — arriving at this moment as aid budgets across major European donors are repackaged as investment rather than grants. Routine immunisation in much of the region relies on Gavi-procured stock that travels through the same air corridors, and the cold chain in those settings was already fragile before any of this began. How long current buffers hold is a function of variables nobody is in a position to forecast confidently. Bob Kitchen, vice-president of emergencies and humanitarian action at the International Rescue Committee, who is based in Nairobi, told NPR that he had not seen a comparable convergence in his career — pandemic, Ukraine and the current crisis included. A UN-managed depot in East Africa is currently holding stocks bound for Sudan, Ethiopia and other acute crises that cannot be released.

Save the Children’s drugs are still in India. As of late April, the strait remains effectively closed despite a conditional ceasefire, with Iran and the United States locked in a dual blockade as Pakistan-mediated talks continue. France and the UK have signalled that they will lead an international defensive mission once a sustainable ceasefire holds. None of that gets a vial to Kandahar this week.

What is the longer-term lesson? Supply chain analysts have been writing it for years, and now have a vivid case in front of them. A global medicine system optimised for cost works only as long as nothing goes wrong in three or four key chokepoints. Hormuz is one. The Suez and the Bab al-Mandeb are others. The Panama Canal is a fourth. The system functions until it doesn’t, and the people who feel the failure first are rarely the people the system was designed for.

Soeripto’s sentence is worth reading again. The transport for the drugs is more expensive than the drugs themselves. It is not, on its face, a sentence about war or oil or even shipping. It is a sentence about who, in a system held together by chokepoints, ultimately pays the bill. The strait will reopen. The arithmetic — and the question of who absorbs it — will not.

The post The Strait That Ships the World’s Vaccines appeared first on Medika Life.

Many of us may take multiple medications daily, and we depend on our prescriber’s ability to monitor those that are safe for us and exclude those that may be problematic. Anyone who wishes to be safer may do a bit of their research, and that’s fine. It does not mean you are suspicious; you only wish to ensure there’s no problem.

Hundreds of medications are listed, and it’s almost impossible for anyone to know if a medication could cause one of those rare effects for you. It is, therefore, in your best interest to be vigilant for these effects. In addition to being aware of the side effects, most patients would not know that the number of side effects may increase as the number of people taking the medication increases. Not every side effect manifests immediately, and it may require a significant increase in medication usage for it to show up.

How does a side effect enter the PDR? Usually, during clinical trials where drugs are being tested on patients, the principal investigator (PI) and those involved at the clinical sites will note any side effects that subjects report. Occasionally, an ultra-concerned clinical investigator may turn up a problem that isn’t one.

I recall a woman who developed a rash during clinical trials of a medication. Later, researchers determined that her caregiver had caused the rash by applying skin cream to her. The rash, however, continued to appear as a side effect of the drug. Although the rash wasn’t severe wasn’t related to the medication, it suggested that the researcher was very cautious about their protocol records.

Over the past several years, the discovery and prescribing of weight loss drugs (usually GLP-1) have been noted to have some mild side effects, and several studies have indicated what to expect in terms of side effects. Gut bacterial action causes bad breath (Ozempic breath), but it was easily manageable, provided the healthcare prescriber also examined any dental problems.

The Potential Risks

In another study, semaglutide was associated with a prevalence of nausea (44.10%), vomiting (24.58%), and gastroesophageal reflux disease (GERD) (6.28%) in obese individuals.

However, researchers are now expressing additional concerns about side effects that have emerged after tens of thousands of people have used these medications. How do these drugs work, and what are they noting?

By stimulating the body to create more insulin, these drugs decrease blood sugar levels. They also slow food’s passage through the stomach and lessen the sugar released into the bloodstream. When the digestive process is delayed, patients experience prolonged feelings of fullness, which can reduce their caloric intake and lead to weight loss. The action of the drugs would seem beneficial, especially for those who need to control their blood sugar levels and their weight.

But there was an increased risk, however, of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, and interstitial nephritis associated with GLP-1RA use compared to usual care.

Researchers also followed more than 200,000 diabetics taking GLP-1 meds and over 1.7 million diabetics using other medications to decrease blood sugar for around 3.5 years. The study did find that using GLP-1 was not without its hazards. They found these medications were associated with an increased risk of pancreatitis of 146% and an increased risk of arthritis of 11%. But most of the study’s participants were white men in their 60s and 70s with US VA ties. Such a sample would not necessarily provide the most robust results, and future studies need to be much more diverse in the population studied.

The Vanity Factor

Aside from any physical effects, there is also something women especially might be concerned about: Ozempic face. A New York dermatologist came up with this term. It means that losing weight can make your face look older because of the tissue that is being lost. The fact that videos describing it have received millions of views indicates the extent of concern.

But when it comes to treating type 2 diabetes, the GLP-1 RA family provides positive benefits. In addition to a favorable impact on weight and a low risk of hypoglycemia, all medicines in the class have shown substantial reductions in A1C.

Despite some noted adverse side effects, the medications have proven beneficial to a significant number of users. However, as with everything, the benefits and risks must be weighed carefully, and Ozempic face should not be a negative when considering questions of health.

The post Skinnier, Sicker? Weight-Loss Meds Raise Concerns appeared first on Medika Life.

President Trump’s executive order could result in higher US medicines prices because big data will allow payments to be linked more closely to the real value a medicine delivers.

President Trump’s executive order is short on specifics but Bloomberg says that he will direct the US Trade Representative and the US Department of Commerce to take action on “unreasonable or discriminatory policies that suppress drug prices overseas.” Trump is also asking the Department of Health and Human Services to “facilitate direct drug sales to consumers at lower prices paid abroad.”

Pharmaceutical companies look as if they are charging more in the US than in the rest of the world for medicines protected by patents; sometimes they are not. Recently, I was with a client’s US and European commercial teams. With some trepidation, the UK GM announced the price he had negotiated with NICE, the British pricing authority. It was less than half the US list price but, the US general manager said that it was higher than the average price the company actually received in the US. The difference was skimmed off by what economists call “rent seekers” — companies that add no value but are able to add fees or a mark up. These parasitical pharmacy benefits managers and insurers are politically well connected and it has proved very difficult to cut them out of the US supply chain.

Does the US want medicines priced the way they are in the rest of the world?

The American system, beyond big federal programmes, relies on prices that are set through these one-on-one negotiations with various actors who can permit or block access for patients. In most of the rest of the rich world, medicines prices are set for almost all prescriptions through a system of health technology assessments (HTAs). These HTAs typically rely on some mix of assessing the true incremental value of a new medicine and estimating the savings that it could generate in other parts of the health system.

In the UK, for example, NICE typically considers a medicine cost-effective if its incremental cost-effectiveness ratio (ICER) falls between £20,000 and £30,000 per quality-adjusted life year saved (QALY). Interventions below £20,000/QALY are generally approved, while those above £30,000 require additional justification. It may accept ICERs up to £50,000 per QALY for severe conditions such as cancer or neurological illnesses or where it is difficult to measure the benefit exactly. In theory, a QALY equates to one year of life in perfect health. Two years at about 50 percent of perfect health (measured according to criteria such as pain, mobility and self-care) would be one QALY, for example.

Irish agencies require hospitals to consider the broader impact of drug choices on the entire healthcare system, including potential savings from reduced admissions or procedures. Most other countries factor these elements into decisions too. A 2015 study of 15 rich countries concluded that new medicines launched between 1982 and 2015 had saved about five times as much in averted health system costs as they had cost.

If those HTA criteria were applied widely in the US, prices would be much higher than they are in Europe. In the US, life expectancy is growing faster than healthy life expectancy — Americans are sicker for more of their lives than are most people in the world, so the cost of mitigating that poor health will be higher. There is a wealth of information in the International Longevity Centre UK’s Healthy Ageing & Prevention Index. American healthcare costs are much higher than they are anywhere else in the world, so the savings achieved by medicines will be even more impressive.

The real economic benefits of new medicines

What none of the HTA systems yet take into account are the wider societal benefits of prevention and treatment — it is often seen as too complicated. As Professor Rifat Atun and others wrote recently, “an important but often-overlooked mechanism is the benefit of health investments on the broader economy through influences on supply and demand across various other sectors of a country’s economy.”

“Adult immunisation programmes across ten countries and four vaccines showing that [these programmes] offset their costs multiple times through benefits to individuals, the healthcare system, and wider society,” a 2024 paper from the Office of Health Economics reported. “In particular, benefit-cost analysis of the same vaccines showed that adult vaccines can return up to 19 times their initial investment to society, when their significant benefits beyond the healthcare system are monetised,” it concluded

Most health spending is on older people. They, on average, spend more of their income than do younger people so they are disproportionately important drivers of economic growth. They also provide a very large proportion of volunteer hours that enable younger people, especially women, to work more. As experts at Germany’s pioneering WifOR Institute said recently about cancer treatments in Germany, “health investments [are a] driver of economic stability and growth.”

The US is the world’s biggest economy so it realises more benefits from innovative medicines than other countries do. These benefits are getting easier to measure and quantify too: big data means we can track prevention and treatment success and its knock-on impacts throughout the economy more easily month by month.

Obstacles to the executive order

Is this executive order meant to effect change or to distract from other developments? It is too early to say.

Congress may not agree to government taking a role in setting prices outside Medicare and Medicaid, but those still account for about 40 percent of US medicines spending. The Biden Administration initiated negotiation for some medicines for federal programmes and that could probably be extended by executive action.

It is easy to talk about enabling Americans to buy medicines from abroad but that requires the consent of the countries from which they are buying. Canadian or British prices are negotiated based on different health system costs and economic benefits; it is unlikely that foreign governments will want to make it easier for Americans to take advantage of negotiations that do not reflect their own circumstances or choices about healthcare provision and prevention.

The post Executive action may actually drive up medicines prices appeared first on Medika Life.